EGFR and glioblastoma: In the absence of effective EGFR inhibitors in GBM, the investigation of downstream pathways, including signal transducer and activator of transcription (STAT) family transcription factors (TFs), becomes necessary to disrupt this oncogenic signaling axis in GBM.